Your browser doesn't support javascript.
SARS-COV-2 infection might cause transient cutaneous lesions in IBD patients under treatment with adalimumab.
Tursi, Antonio; Tiano, Michele.
  • Tursi A; Territorial Gastroenterology Service, ASL BAT, Andria (BT); Department of Medical and Surgical Sciences, Post-graduate School of Digestive Diseases, Catholic University, Rome. antotursi@tiscali.it.
  • Tiano M; Ambulatory of Dermatology, Sanitary District no. 3, ASL BAT, Andria (BT) - Italy. miketiano@libero.it.
J Gastrointestin Liver Dis ; 30(2): 310-311, 2021 06 19.
Article in English | MEDLINE | ID: covidwho-1282748

Full text: Available Collection: International databases Database: MEDLINE Main subject: Skin Diseases / Adalimumab / COVID-19 Type of study: Case report / Diagnostic study / Prognostic study Topics: Long Covid Limits: Adult / Humans / Male / Middle aged Language: English Journal: J Gastrointestin Liver Dis Journal subject: Gastroenterology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Skin Diseases / Adalimumab / COVID-19 Type of study: Case report / Diagnostic study / Prognostic study Topics: Long Covid Limits: Adult / Humans / Male / Middle aged Language: English Journal: J Gastrointestin Liver Dis Journal subject: Gastroenterology Year: 2021 Document Type: Article